Generic name: carbamazepine
Dosage form: capsule, extended release
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
The recommended initial dose of EQUETRO is 200 mg administered twice daily. The dose may be increased by 200 mg per day to achieve optimal clinical response. Doses higher than 1600 mg per day have not been studied in mania associated with bipolar disorder.
When discontinuing treatment, reduce the dose gradually and avoid abrupt discontinuation in order to decrease the risk of seizure [see Warnings and Precautions (5.6)].
Monitoring Serum Carbamazepine Concentration
Monitoring serum carbamazepine concentrations may be useful for dose selection, minimizing toxicity, and verifying drug compliance, especially in clinical conditions in which alterations in EQUETRO metabolism can occur (e.g., drug interactions) [see Drug Interactions (7)].
Laboratory Testing Prior to Dosing
Prior to initiating treatment with EQUETRO, test patients with ancestry in genetically at-risk populations for the presence of the HLA-B*1502 allele. The high resolution genotype test is positive if one or two HLA-B*1502 alleles are present. Avoid use of EQUETRO in patients testing positive for the allele, unless the benefit clearly outweighs the risk [see Boxed Warning, Warnings and Precautions (5.1)].
Prior to initiating EQUETRO in all patients, obtain a pre-treatment complete blood count including platelets and differential. Monitor CBC periodically [see Warnings and Precautions (5.2)].